Your browser doesn't support javascript.
loading
An expanded universe of cancer targets.
Hahn, William C; Bader, Joel S; Braun, Theodore P; Califano, Andrea; Clemons, Paul A; Druker, Brian J; Ewald, Andrew J; Fu, Haian; Jagu, Subhashini; Kemp, Christopher J; Kim, William; Kuo, Calvin J; McManus, Michael; B Mills, Gordon; Mo, Xiulei; Sahni, Nidhi; Schreiber, Stuart L; Talamas, Jessica A; Tamayo, Pablo; Tyner, Jeffrey W; Wagner, Bridget K; Weiss, William A; Gerhard, Daniela S.
Afiliação
  • Hahn WC; Dana-Farber Cancer Institute, Department of Medical Oncology, 450 Brookline Avenue, Boston, MA, USA. Electronic address: william_hahn@dfci.harvard.edu.
  • Bader JS; Department of Biomedical Engineering and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Braun TP; Knight Cancer Institute and Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA.
  • Califano A; Department of Systems Biology, Biomedical Informatics, Biochemistry and Molecular Biophysics, and Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
  • Clemons PA; Broad Institute, 415 Main Street, Cambridge, MA, USA.
  • Druker BJ; Knight Cancer Institute and Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA.
  • Ewald AJ; Department of Cell Biology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Fu H; Department of Pharmacology and Chemical Biology, Emory Chemical Biology Discovery Center, and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
  • Jagu S; Office of Cancer Genomics, Center for Cancer Genomics, National Cancer Institute, NIH, Bethesda, MD, USA.
  • Kemp CJ; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Kim W; Moores Cancer Center, Center for Novel Therapeutics and Department of Medicine, UC San Diego, La Jolla, CA, USA.
  • Kuo CJ; Hematology Division, Stanford University School of Medicine, Stanford, CA, USA.
  • McManus M; Department of Microbiology and Immunology, UCSF Diabetes Center, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
  • B Mills G; Department of Cell, Development and Cancer Biology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA.
  • Mo X; Department of Pharmacology and Chemical Biology, Emory Chemical Biology Discovery Center, and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
  • Sahni N; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX, USA.
  • Schreiber SL; Broad Institute, 415 Main Street, Cambridge, MA, USA.
  • Talamas JA; Dana-Farber Cancer Institute, Department of Medical Oncology, 450 Brookline Avenue, Boston, MA, USA.
  • Tamayo P; Moores Cancer Center, Center for Novel Therapeutics and Department of Medicine, UC San Diego, La Jolla, CA, USA.
  • Tyner JW; Knight Cancer Institute, Oregon Health & Science University and Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
  • Wagner BK; Broad Institute, 415 Main Street, Cambridge, MA, USA.
  • Weiss WA; Departments of Neurology, Neurological Surgery, Pediatrics, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
  • Gerhard DS; Office of Cancer Genomics, Center for Cancer Genomics, National Cancer Institute, NIH, Bethesda, MD, USA.
Cell ; 184(5): 1142-1155, 2021 03 04.
Article em En | MEDLINE | ID: mdl-33667368
ABSTRACT
The characterization of cancer genomes has provided insight into somatically altered genes across tumors, transformed our understanding of cancer biology, and enabled tailoring of therapeutic strategies. However, the function of most cancer alleles remains mysterious, and many cancer features transcend their genomes. Consequently, tumor genomic characterization does not influence therapy for most patients. Approaches to understand the function and circuitry of cancer genes provide complementary approaches to elucidate both oncogene and non-oncogene dependencies. Emerging work indicates that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes. Here we describe a framework for this expanded list of cancer targets, providing novel opportunities for clinical translation.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Neoplasias Limite: Animals / Humans Idioma: En Revista: Cell Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Neoplasias Limite: Animals / Humans Idioma: En Revista: Cell Ano de publicação: 2021 Tipo de documento: Article